- Home
- CPRX vs CORT Comparison
CPRX vs CORT Comparison
Compare CPRX & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPRX | CORT |
|---|---|---|
| Founded | 2002 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.7B |
| IPO Year | 2006 | 2001 |
Fundamental Metrics
Financial Performance| Metric | CPRX | CORT |
|---|---|---|
| Price | $31.28 | $69.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $35.00 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 2.9M | 1.2M |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.24 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | $119,072,803.00 | ★ $761,407,000.00 |
| Revenue This Year | $9.20 | $26.08 |
| Revenue Next Year | $10.51 | $26.98 |
| P/E Ratio | $62.58 | ★ N/A |
| Revenue Growth | ★ 16.39 | 12.79 |
| 52 Week Low | $19.05 | $28.66 |
| 52 Week High | $32.56 | $91.00 |
Technical Indicators
Market Signals| Indicator | CPRX | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 72.86 | 84.33 |
| Support Level | $31.00 | $68.20 |
| Resistance Level | $31.33 | $90.00 |
| Average True Range (ATR) | 0.08 | 2.46 |
| MACD | -0.19 | 1.04 |
| Stochastic Oscillator | 81.94 | 97.25 |
Price Performance
Historical ComparisonAbout CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.